AI for Glycemic Events Detection Via ECG in a Pediatric Population

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

64 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-04-12

Study Completion Date

2023-04-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Paediatric Type 1 Diabetes (T1D) patients are at greater risk for developing severe hypo and hyperglycaemic events due to poor glycaemic control and incorrect Insulin administration. To reduce the risk of adverse events, patients need to achieve the best possible glycaemic control through frequent blood glucose monitoring with finger prick or Continuous Glucose Monitoring (CGM) systems. However, several non-invasive techniques have been proposed aiming at exploiting changes in physiological parameters based on glucose levels. The overall objective of this study is to validate a deep learning algorithm to detect glycaemic events using electrocardiogram (ECG) signals collected through non-invasive device.

This observational single-arm study will enrol participants with T1D aged less than 18 years old who already use CGM device. Participants will wear an additional non-invasive wearable device, for recording physiological data (e.g. ECG, breathing waveform, 3-axis acceleration) for three days. ECG variables (e.g. heart rate variability features), respiratory rate, physical activity, posture and glycaemic measurements driven through ECG variables and other physiological signals (e.g. the frequency of hypo or hyperglycaemic events, the time spent in hypo- or hyperglycaemia and the time in range) are the main outcomes. A quality-of-life questionnaire will be administered to collect secondary outcomes. Data collected will be used to design, develop and validate the personalised and generalized classifiers based on a deep-learning artificial intelligence (AI) algorithm developed during the pilot study, able to automatically detect hypoglycaemic events by using few ECG heartbeats recorded with wearable devices.

This study is a validation study that will carry out additional tests on a larger diabetes sample population, to validate the previous promising pilot results that were based on four healthy adult subjects. Therefore, this study will provide evidence on the reliability of the deep-learning artificial intelligence algorithms investigators developed, in detecting glycaemic events in paediatric diabetic patients in free-living conditions. Additionally, this study aims to develop the generalized AI model for the automated glycaemic events detection on real-time ECG.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prevention of Severe Hypoglycaemia With Hypo-Safe Hypoglycaemia Alarm Device

NCT01178476

Type 1 Diabetes

WITHDRAWN NA

Prevention of Hypoglycaemia by Oral 40% Destrogel

NCT04185766

Hypoglycaemia Neonatal

COMPLETED NA

Hyperglycemia in Patients With Takotsubo Syndrome

NCT04684004

Takotsubo Cardiomyopathy

COMPLETED

Children with Diabetic Ketoacidosis

NCT06599203

Diabetic Ketoacidosis

NOT_YET_RECRUITING

Lactate to Treat Hypoglycemia

NCT01387477

Hypoglycemia

WITHDRAWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

As per inclusion criteria, the study participants continue to use their CGM device they are already using. During their routine diabetes hospital visit, the participants are asked to wear an additional wearable device, Medtronic Zephyr BioPatch, for recording the physiological data for a period of up to three days. After receiving the training session and relevant information about the study, the participants are allowed to return home with the wearable device attached. During the hospital visit, the quality of life questionnaire for paediatric patients (PEdsQL) is submitted to recruited patients. They are asked to answer questions on how T1D affects their daily activities.

During the monitoring days, patients can continue their daily activities undisturbed, without any changes in either physical activities or diet. In this way, data gathered from free-living conditions are obtained. They should wear the sensor during the day and the night and remove it while showering. The device should be approximately charged every 12-hours. For this reason, patients were provided with two devices. While wearing the second device the one used during the day should be recharged and vice versa. Patients receive regular contact from the research team not only to check on their safety and wellbeing, but also to ensure the data collection is successful. At the end of the third day, patients should return the devices to the hospital.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

type1diabetes Pediatrics

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

type1diabetes patients who use CGM

Males and females diagnosed with T1D, aged less than 18 years old who are currently under the care of the Unit of Endocrinology and Diabetes of Bambino Gesù Children's Hospital, Rome, Italy and who already use continuous glucose monitoring (CGM) systems are eligible to be involved in the study. Participants will wear an additional non-invasive wearable device, Medtronic Zephyr BioPatch, for recording physiological data for three days.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age less than 18 years old
* Diagnosed with type 1 diabetes
* Use of continuous glucose monitoring systems (CGM)

Exclusion Criteria

* Use of standard finger prick glucometer to measure glycemic values
* Be pregnant or becoming pregnant during the study
* Coexistence of celiac disease
* Coexistence of non-diabetic hypoglycemia
* Coexistence of cardiovascular pathologies and cardiac arrhythmias

Minimum Eligible Age

4 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No